These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult. Chen DB; Liu XY; Kong FZ; Jiang Q; Shen DH J Clin Pathol; 2021 Nov; 74(11):697-703. PubMed ID: 34011618 [TBL] [Abstract][Full Text] [Related]
34. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702 [TBL] [Abstract][Full Text] [Related]
35. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S; Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985 [TBL] [Abstract][Full Text] [Related]
36. Fatal donor-derived Epstein-Barr virus-associated post-transplant lymphoproliferative disorder following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome. Ho AY; Adams S; Shaikh H; Pagliuca A; Devereux S; Mufti GJ Bone Marrow Transplant; 2002 May; 29(10):867-9. PubMed ID: 12058237 [TBL] [Abstract][Full Text] [Related]
37. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts. Hoegh-Petersen M; Goodyear D; Geddes MN; Liu S; Ugarte-Torres A; Liu Y; Walker JT; Fonseca K; Daly A; Duggan P; Stewart D; Russell JA; Storek J Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556 [TBL] [Abstract][Full Text] [Related]
38. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center]. Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748 [TBL] [Abstract][Full Text] [Related]
40. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute. Hou HA; Yao M; Tang JL; Chen YK; Ko BS; Huang SY; Tien HF; Chang HH; Lu MY; Lin TT; Lin KH; Hsiao CH; Lin CW; Chen YC Bone Marrow Transplant; 2009 Feb; 43(4):315-21. PubMed ID: 18836488 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]